Can a biotech unicorn break into the record books with a $600M IPO? Stéphane Bancel has a fortune riding on the answer
Stéphane Bancel’s life is about to change dramatically.
The Moderna CEO and his crew have posted the details on their shot at the biggest biotech IPO in the industry’s history. And Bancel will have a personal fortune of more than $700 million riding on the outcome — if they can score a record success.
In a new filing Moderna $MRNA got around to outlining who controls the stock at the messenger RNA company, which has a valuation scraping $7.8 billion under a bullish scenario. Flagship — represented by Noubar Afeyan, who seeded the company at the venture group — weighs in at the top rank with 18% of the shares.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.